Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma
- 1 June 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Surgical Pathology
- Vol. 34 (6), 767-776
- https://doi.org/10.1097/pas.0b013e3181d96231
Abstract
The importance of HER2 status in breast cancer management has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. There is no consensus as to the best method for assessing HER2 status. Disadvantages of fluorescence in situ hybridization (FISH) testing include longer time required for staining and scoring slides, requirements for specialized training and fluorescence microscopy, and loss of the signal due to quenching of the fluorescent dye. Silver-enhanced in situ hybridization (SISH) is a rapid fully automated assay providing permanently stained slides that are interpreted by conventional bright field microscopy which enables pathologists to evaluate slides within the context of tissue morphology. This study evaluates the concordance between SISH and FISH assays in determining the status of HER2 gene amplification in a cohort of 298 primary invasive breast carcinomas. Furthermore, we assessed in detail the variables contributing to interobserver interpretive reproducibility of HER2 SISH among 10 pathologists. HER2 was quantified using the ratio of HER2 to CHR17 signals using the conventional historical interpretation scale and also by the American Society of Clinical Oncology/College of American Pathologists reporting scheme. For SISH status determined by consensus among 10 pathologists, overall concordance between SISH and FISH was identified in 288 of 298 cases (96.6%) using the conventional Food and Drug Administration approved criteria. Overall agreement was observed in 282 of 285 cases (98.9%) using the American Society of Clinical Oncology/College of American Pathologists result reporting scheme (with equivocal cases removed). In conclusion, SISH represents a novel approach for the determination of HER2 status in breast cancer. The overall concordance between SISH and FISH is excellent, and the interpretation of SISH results by pathologists is most reproducible using the HER2/CHR17 ratio.Keywords
This publication has 41 references indexed in Scilit:
- Chromogenic In Situ HybridizationAmerican Journal of Clinical Pathology, 2009
- Bright-field In Situ Hybridization for HER2 Gene Amplification in Breast Cancer Using Tissue MicroarraysDiagnostic Molecular Pathology, 2009
- Real Time RT-PCR Approach for the Evaluation of ERBB2 Overexpression in Breast Cancer Archival Samples: A Comparative Study With FISH, SISH, and ImmunohistochemistryDiagnostic Molecular Pathology, 2008
- Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and PathologistsThe Journal of Molecular Diagnostics, 2008
- Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American PathologistsVirchows Archiv, 2007
- Analytical Validation and Interobserver Reproducibility of EnzMet GeneProThe American Journal of Surgical Pathology, 2005
- Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancerBritish Journal of Cancer, 2003
- Chromogenic In Situ Hybridization: A Novel Approach to a Practical and Sensitive Method for the Detection of HER2 Oncogene in Archival Human Breast CarcinomaLaboratory Investigation, 2002
- HER2/Neu: mechanisms of dimerization/oligomerizationOncogene, 2000
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998